Is Tenapanor safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Tenapanor. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Tenapanor is virtually not absorbed systemically, with undetectable plasma concentrations following oral administration. Tenapanor and its major metabolite were not detected in the breastmilk of lactating women. No special precautions are necessary.
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. A clinical lactation study was conducted in seven healthy women. Following oral administration of tenapanor 50 mg twice daily for 3 days, milk samples were collected before a dose then at 1, 2, 4, 6, 8, and 24 hours after the dose. The concentrations of tenapanor and its major metabolite were undetectable (<1 mcg/L) in all milk samples collected over 24 hours after a dose.[1]
Infant Levels. Relevant published information was not found as of the revision date.
“No published information” means the studies do not exist yet — not that Tenapanor is known to be harmful, and not that it is known to be safe. Your prescriber or pharmacist can weigh your baby's age and whether a better-studied alternative would do the same job. Worth asking before stopping a medicine you need.
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Tenapanor” (tenapanor). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.